Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01040338 · ClinicalTrials.gov registry record
Effects of Nicotine on Brain Opioid Receptors
A clinical trial, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- 15
- Enrollment target
NCT01040338: Clinical Trial study, sponsored by University of Pennsylvania.
NCT01040338 is a clinical trial that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01040338 was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- 15 participants
- Enrollment target
Study Summary
A substantial body of evidence implicates the endogenous opioid system, and the mu opioid receptor (MOR) in particular, in the reinforcing effects of drugs of abuse, including nicotine. A single nucleotide polymorphism (SNP) in the mu opioid receptor gene (OPRM1 Asp40) is associated with the ability to quit smoking, as well as nicotine reward and withdrawal symptoms. However, the precise mechanism through which this SNP influences nicotine dependence remains unresolved. This positron emission tomography (PET) study will examine whether this OPRM1 SNP alters MOR binding in response to nicotine in human smokers. Specifically, we will use \[11 C\]carfentanil PET imaging to assess the effects of intravenous (IV) nicotine versus saline (within-subject) on MOR binding potential in 24 chronic smokers genotyped prospectively and stratified by OPRM1 genotype.
Interventions
- DRUG Nicotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01040338
The ClinicalTrials.gov registry entry for NCT01040338 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nicotine is the first listed.
NCT01040338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01040338 about?
NCT01040338 is a clinical study titled "Effects of Nicotine on Brain Opioid Receptors". A substantial body of evidence implicates the endogenous opioid system, and the mu opioid receptor (MOR) in particular, in the reinforcing effects of drugs of abuse, including nicotine. A single nucleotide polymorphism (SNP) in the mu opioid receptor gene (OPRM1 Asp40) is associated with the ability...
What is the current status of trial NCT01040338?
This trial is currently terminated. The enrollment target is 15 participants. The study started on 2010-02. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01040338?
The interventions under investigation include: Nicotine (DRUG).
Who is sponsoring clinical trial NCT01040338?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.